enGene is a company focused on advancing detalimogene, an investigational non-viral gene therapy for non-muscle invasive bladder cancer (NMIBC). The company aims to make genetic medicines mainstream by developing non-viral therapeutics that can be delivered directly to mucosal tissues. Detalimogene has received Regenerative Medicine Advanced Therapy (RMAT) and Fast Track designations from the U.S. Food and Drug Administration (FDA), recognizing its potential to address unmet medical needs. enGene's proprietary DDX® platform is a breakthrough in non-viral genetic medicine, specifically targeting mucosal tissues. The company is deeply focused on improving patient outcomes and has developed innovative solutions for urological cancers, with the LEGEND Clinical Trial as part of their pipeline. Founded by enGene Therapeutics Inc., the company was established to deliver results-driven, collabor
Browsing, company names, locations and sectors are always free. A free account adds 5 contact releases every month — e-mail and phone, view or export. Need more? Contact packs start at 19 € for 50, or upgrade to a monthly plan.
Yes — no card required. Browsing is always free, and a free account adds 5 contact releases every month.
Your first 5 contact releases each month are included in the free account. After that, packs start at 19 € for 50 contacts (view or export), or a monthly plan for regular use.
Companies are harvested from the open web — registers, websites and industry directories — not self-registered sign-ups. Contact details are shown only once you use a release or credit, never invented.